Pavel Kapysh / Shutterstock.com
Sandoz, a subsidiary of Swiss pharmaceutical company Novartis, has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel (etanercept) until 2029.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sandoz, patent, Enbrel, Amgen, patents, Federal Circuit, Roche, Federal Circuit, pharmaceutical, Novartis